These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 12205361)

  • 1. Integrating GP IIb/IIIa inhibition into treatment strategies for acute ST-elevation myocardial infarction.
    Kandzari DE; Roe MT
    J Invasive Cardiol; 2002 Sep; 14(9):565-74. PubMed ID: 12205361
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
    Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of platelet glycoprotein IIb/IIIa as augmenters of thrombolysis.
    Eccleston D; Topol EJ
    Coron Artery Dis; 1995 Dec; 6(12):947-55. PubMed ID: 8723017
    [No Abstract]   [Full Text] [Related]  

  • 4. Platelet GP IIb/IIIa inhibition in unstable angina and non-ST segment elevation MI: application of the ACC/AHA guidelines.
    Young JJ; Choo JK; Kereiakes DJ; ;
    J Invasive Cardiol; 2003 Feb; 15(2):102-7; quiz 108. PubMed ID: 12556626
    [No Abstract]   [Full Text] [Related]  

  • 5. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
    Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
    Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
    Lefebvre CW; Hoekstra JW; Bonaca M; Giugliano R
    J Emerg Med; 2009 Feb; 36(2):162-70. PubMed ID: 18353601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction in a tertiary referral medical center in a developing country.
    Abdallah M; Karrowni W; Dakik HA
    Int J Cardiol; 2007 Jan; 114(2):282-3. PubMed ID: 16581145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
    Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ
    Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet glycoprotein IIb/IIIa inhibitor therapy in non-ST segment elevation acute coronary syndromes.
    Elmouchi DA; Bates ER
    Minerva Cardioangiol; 2003 Oct; 51(5):547-60. PubMed ID: 14551523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycoprotein IIb/IIIa inhibitors: therapeutic applications in acute ST-segment elevation myocardial infarction.
    Campbell KR; Cantor W; Sketch M; Ohman EM
    Am Heart J; 2000 Dec; 140(6 Suppl):S115-24. PubMed ID: 11100005
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
    Jolly SS; Faxon DP; Fox KA; Afzal R; Boden WE; Widimsky P; Steg PG; Valentin V; Budaj A; Granger CB; Joyner CD; Chrolavicius S; Yusuf S; Mehta SR
    J Am Coll Cardiol; 2009 Jul; 54(5):468-76. PubMed ID: 19628124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines.
    Antman EM
    Am Heart J; 2003 Oct; 146(4 Suppl):S18-22. PubMed ID: 14564302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycoprotein IIb/IIIa inhibitors and the guidelines for treatment of non-ST-elevation myocardial infarction.
    Coplan NL
    J Am Coll Cardiol; 2004 Mar; 43(5):926-7; author reply 927-8. PubMed ID: 14998642
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
    Huynh T; Theroux P; Snapinn S; Wan Y;
    Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of glycoprotein IIIa A1/A2 gene polymorphism on one-year outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
    Kozieradzka A; Kamiński KA; Pepiński W; Janica J; Korecki J; Skolimowski K; Frankowska E; Kralisz P; Bonda TA; Dobrzycki S; Musiał WJ
    Kardiol Pol; 2006 Dec; 64(12):1350-5; discussion 1356. PubMed ID: 17206538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The year in non-ST-segment elevation acute coronary syndromes.
    Giugliano RP; Braunwald E
    J Am Coll Cardiol; 2005 Sep; 46(5):906-19. PubMed ID: 16139143
    [No Abstract]   [Full Text] [Related]  

  • 17. Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes.
    Dabbous OH; Anderson FA; Gore JM; Eagle KA; Fox KA; Mehta RH; Goldberg RJ; Agnelli G; Steg PG;
    Heart; 2008 Feb; 94(2):159-65. PubMed ID: 17575335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.
    De Luca G; Marino P
    Am J Emerg Med; 2009 Jul; 27(6):683-90. PubMed ID: 19751625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
    J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients.
    Tricoci P; Peterson ED
    J Interv Cardiol; 2006 Oct; 19(5):449-55. PubMed ID: 17020570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.